BioCardia, Inc. (BCDA)
$1.18+$0.01 (+1.21%) Today
Peter Altman - OfficerPeter Altman - OfficerPeter Altman - OfficerPeter Altman - OfficerPeter Altman - OfficerPeter Altman - OfficerPeter Altman - OfficerBioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 14 | 141,100 | $132K |
| Grant or award | 12 | 387,260 | |
| Tax withholding / forfeiture | 3 | 95,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
55 Form 4 filings on record, the earliest from Oct 16, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,400 | $0.93 | $5K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,900 | $0.92 | $2K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,000 | $0.78 | $4K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 500 | $0.83 | $415 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 2,800 | $0.88 | $2K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,500 | $0.86 | $1K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,000 | $0.90 | $900 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,000 | $0.94 | $940 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,500 | $0.97 | $5K | |
 Simon H. Stertzer - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
 Marvin Slosman - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Peter Altman - Officer | Tax withholding / forfeiture | Common Stock | 54,606 | $1.24 | $68K | |
| Peter Altman - Officer | Grant or award | Stock Option (right to buy) | 57,688 | $0.00 | - | |
| David McClung - Officer | Tax withholding / forfeiture | Common Stock | 23,125 | $1.24 | $29K | |
| David McClung - Officer | Grant or award | Stock Option (right to buy) | 41,501 | $0.00 | - | |
| Edward M. Gillis - Officer | Tax withholding / forfeiture | Common Stock | 17,269 | $1.24 | $21K | |
| Edward M. Gillis - Officer | Grant or award | Stock Option (right to buy) | 29,442 | $0.00 | - | |
| Andrew Scott Blank - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Jim L. Allen - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
 Jay M. Moyes - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Bill Facteau - Director | Grant or award | Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Peter Altman - Officer | Grant or award | Common Stock | 110,625 | $1.20 | $133K | |
| David McClung - Officer | Grant or award | Common Stock | 60,483 | $1.20 | $73K | |
| Edward M. Gillis - Officer | Grant or award | Common Stock | 39,521 | $1.20 | $47K | |
| Simon H. Stertzer - Director | Open-market purchase | Common Stock | 70,200 | $0.92 | $65K | |
| Simon H. Stertzer - Director | Open-market purchase | Common Stock | 39,000 | $1.00 | $39K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,500 | $0.85 | $1K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 800 | $0.96 | $768 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,000 | $0.85 | $4K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 200 | $0.95 | $190 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 1,500 | $0.92 | $1K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,700 | $0.92 | $5K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,100 | $1.02 | $5K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,000 | $1.11 | $6K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 600 | $1.23 | $738 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 400 | $1.23 | $492 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 600 | $1.24 | $744 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 300 | $1.22 | $366 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 5,000 | $1.13 | $6K | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 600 | $1.32 | $792 | |
| Peter Altman - Officer | Open-market purchase | Common Stock | 300 | $1.34 | $402 | |
| Simon H. Stertzer - Director | Open-market purchase | Common Stock | 398,400 | $1.25 | $498K | |
| Simon H. Stertzer - Director | Open-market purchase | Warrant (right to buy) | 398,400 | - | - |
BioCardia, Inc. (BCDA) had 21 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for BCDA runs to 55 Form 4 filings, the earliest from 2024-10-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
14 insider purchases of BCDA were filed in the last 90 days, totaling $132K.
No insider sales of BCDA were filed in the last 90 days. 1 sale is on record for this company.
This page tracks BCDA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add BCDA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
